Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

While Hims offers more options for sexual health and hair loss, Roman offers more options overall. Here’s our full breakdown of Hims vs. Roman for erectile dysfunction, hair loss, and more.

Hims & Hers Health, Inc. (NYSE:HIMS) announced the acquisition of a California-based peptide facility to enhance its domestic supply chain and meet rising demand for personalized medications.

Both Hims and Keeps offer viable options for treating hair loss. Choosing between the two could come down to product choice, customer service, and personal preference. Share on Pinterest Find out ...

Shares of the pharmaceutical upstart are flying Tuesday morning -- up 7.3% through 10:20 a.m. ET ... As regards tirzepatide, the FDA declared it "does not intend to take action against compounders ...

Hims & Hers ramped up its marketing spend in the quarter, but was able to show marketing leverage, with marketing expense as a percentage of revenue falling year over year. Marketing spending ...

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s expectations, but shares fell hard in after-hours trading ...

This goes to show ... that HIMS's personalized care is a differentiator. Still, the more the valuation rises, the more impact the risks can have on the stock price if they ever end up being ...

with HIMS's price up by 6.86%, positioned at $33.65. RSI indicators show the stock to be is currently neutral between overbought and oversold. Earnings announcement expected in 47 days.

Hims & Hers Health reports fourth-quarter revenue of $481.14 million, beating estimates of $470.31 million. Citigroup analyst Daniel Grosslight maintains Hims & Hers with a Sell and raises the ...